Rallybio Corporation (RLYB)

NASDAQ: RLYB · IEX Real-Time Price · USD
8.87
0.12 (1.37%)
At close: Jan 14, 2022 4:00 PM
8.82
-0.05 (-0.56%)
After-hours:Jan 14, 2022 4:00 PM EST
Market Cap284.99M
Revenue (ttm)n/a
Net Income (ttm)-45.12M
Shares Out32.13M
EPS (ttm)-5.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,953
Open8.69
Previous Close8.75
Day's Range8.35 - 8.93
52-Week Range8.06 - 25.78
Betan/a
AnalystsStrong Buy
Price Target30.00 (+238.2%)
Earnings Daten/a

About RLYB

Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Since our launch in January 2018, we have acquired a portfolio of promising product candidates that consists of five programs, and we are focused on further expanding our portfolio with the goal of making a profound impact on the lives of eve...

IndustryBiotechnology
IPO DateJul 29, 2021
CEOMartin W. Mackay, Ph.D.
Employees31
Stock ExchangeNASDAQ
Ticker SymbolRLYB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Rallybio stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 238.22% from the latest price.

Price Target
$30.00
(238.22% upside)
Analyst Consensus: Strong Buy

News

Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

1 week ago - Business Wire

Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy?

Rallybio (RLYB) has been struggling lately, but the selling pressure may be coming to an end soon.

2 weeks ago - Zacks Investment Research

Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocyt...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

1 month ago - Business Wire

Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

1 month ago - Business Wire

Rallybio to Present at the Jefferies London Healthcare Conference

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

2 months ago - Business Wire

Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies fo...

2 months ago - Business Wire

Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights

NEW HAVEN, Conn.--(BUSINESS WIRE)---- $RLYB #FNAIT--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transfor...

4 months ago - Business Wire

Andreas Halvorsen Gets a Healthy Dose of Rallybio

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed a stake in Rallybio Corp. ( RLYB , Financial) earlier this week, seeing a value opportunity in a newly public company.

5 months ago - GuruFocus

Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Pu...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- #Rallybio--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming ...

5 months ago - Business Wire